ATE202706T1 - Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom - Google Patents

Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom

Info

Publication number
ATE202706T1
ATE202706T1 AT95933922T AT95933922T ATE202706T1 AT E202706 T1 ATE202706 T1 AT E202706T1 AT 95933922 T AT95933922 T AT 95933922T AT 95933922 T AT95933922 T AT 95933922T AT E202706 T1 ATE202706 T1 AT E202706T1
Authority
AT
Austria
Prior art keywords
glaucoma
treatment
inderivatives
deoxyprostagland
deoxyprostaglandins
Prior art date
Application number
AT95933922T
Other languages
English (en)
Inventor
Mark R Hellberg
Thomas R Dean
Paul W Zinke
Robert D Selliah
John E Bishop
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of ATE202706T1 publication Critical patent/ATE202706T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95933922T 1994-09-30 1995-09-25 Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom ATE202706T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31627594A 1994-09-30 1994-09-30
US08/480,707 US5698733A (en) 1994-09-30 1995-06-07 Use of 9-deoxy prostaglandin derivatives to treat glaucoma
PCT/US1995/012171 WO1996010407A1 (en) 1994-09-30 1995-09-25 Use of 9-deoxy prostaglandin derivatives to treat glaucoma

Publications (1)

Publication Number Publication Date
ATE202706T1 true ATE202706T1 (de) 2001-07-15

Family

ID=26980337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933922T ATE202706T1 (de) 1994-09-30 1995-09-25 Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom

Country Status (9)

Country Link
US (1) US5698733A (de)
EP (1) EP0783308B1 (de)
JP (1) JPH10506893A (de)
CN (1) CN1084189C (de)
AT (1) ATE202706T1 (de)
AU (1) AU701808B2 (de)
DE (1) DE69521620T2 (de)
MX (1) MX9702349A (de)
WO (1) WO1996010407A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169111B1 (en) 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
US5814660A (en) * 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
AU5436198A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AU1607100A (en) 1998-11-06 2000-05-29 Alcon Laboratories, Inc. Upregulation of endogenous prostaglandins to lower intraocular pressure
AU1607200A (en) * 1998-11-06 2000-05-29 Alcon Laboratories, Inc. Use of an inducible gene for the enzyme cyclooxygenase to lower intraocular pressure
US6160013A (en) * 1998-12-17 2000-12-12 Alcon Laboratories, Inc. 14-aza prostaglandins for the treatment of glaucoma and ocular hypertension
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
IL134241A (en) 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
WO2001066518A1 (en) * 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E-ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
GB0112699D0 (en) 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
KR100602549B1 (ko) * 2001-07-17 2006-07-20 파마시아 앤드 업존 캄파니 엘엘씨 라타노프로스트 제조를 위한 방법
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
GB0329379D0 (en) * 2003-12-19 2004-01-21 Johnson Matthey Plc Prostaglandin synthesis
US7109371B2 (en) * 2004-01-05 2006-09-19 Johnson Matthey Public Limited Company Prostaglandin synthesis
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
EP2135860A1 (de) * 2008-06-20 2009-12-23 Sandoz AG Verbesserter Herstellungsverfahren für Bimatoprost
EP2143712A1 (de) 2008-07-10 2010-01-13 Sandoz AG Verbessertes Verfahren zur Herstellung von Prostaglandinen und Prostaglandin-Analogen
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
NZ628266A (en) * 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN102690219A (zh) * 2011-03-24 2012-09-26 天津信汇制药股份有限公司 纯化贝美前列素的方法
EP2976080B1 (de) 2013-03-15 2019-12-25 Aerie Pharmaceuticals, Inc. Konjugate von isoquinolinverbindungen und prostaglandinen
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350971A (en) * 1971-05-11 1974-04-24 Imp Chemi Als Ind Ltd Cyclopentane derivatives
GB1539268A (en) * 1976-12-23 1979-01-31 Ici Ltd Prostane derivatives
EP0286903B2 (de) * 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5093329A (en) * 1990-03-12 1992-03-03 Allergan, Inc. Intraocular pressure reducing prostaglandin-like 7-oxabicyclo derivatives
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
ES2166353T3 (es) * 1992-03-19 2002-04-16 R Tech Ueno Ltd Tratamiento de la hipertension ocular con beta-bloqueantes y derivados del acido prostanoico.
JPH06100529A (ja) * 1992-09-22 1994-04-12 Ono Pharmaceut Co Ltd プロスタグランジンＦ２βイソプロピルエステル、その製造方法およびそれを含有する薬剤
US5468778A (en) * 1992-09-24 1995-11-21 Allergan, Inc. Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives
US5385945A (en) * 1992-10-21 1995-01-31 Allergan, Inc. 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds

Also Published As

Publication number Publication date
DE69521620T2 (de) 2001-10-18
US5698733A (en) 1997-12-16
JPH10506893A (ja) 1998-07-07
AU701808B2 (en) 1999-02-04
EP0783308A1 (de) 1997-07-16
MX9702349A (es) 1997-06-28
WO1996010407A1 (en) 1996-04-11
CN1084189C (zh) 2002-05-08
DE69521620D1 (de) 2001-08-09
AU3639895A (en) 1996-04-26
EP0783308B1 (de) 2001-07-04
CN1163568A (zh) 1997-10-29

Similar Documents

Publication Publication Date Title
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE420857T1 (de) Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
DE3788984D1 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ES2216055T3 (es) Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
ATE271390T1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69705421D1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
DE69430521D1 (de) Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE69728536D1 (de) Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis
TR200200278T2 (tr) Kalsilitik bileşimler
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
BR9611904A (pt) Dioxidos de ditiazol
ATE195072T1 (de) Verwendung von 6,7-substituierten-2- aminotetraline zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von septischem schock, und antipyretischer und antientzündlicher zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties